Akouos Reports Third Quarter 2022 Financial Results and Provides Business Highlights

-Received clearance from FDA for the AK-OTOF IND application to initiate a Phase 1/2, first in human, pediatric clinical trial

-Continued progress toward planned IND submission for AK-antiVEGF in 2023